Partnership / Collaboration · GCC · Announced 8 Jun 2026
Novo Nordisk → Emirates Drug Establishment
Novo Nordisk has signed an MoU with the UAE's new federal drug regulator, the Emirates Drug Establishment, on local manufacturing, supply-chain security and faster regulatory access — as GLP-1 makers compete for a UAE production footprint.
Parties: Novo Nordisk (Denmark) → Emirates Drug Establishment (EDE) (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- United Arab Emirates
- Therapeutic area
- Metabolic / Diabetes
- Asset
- MoU on local pharmaceutical manufacturing, supply-chain security, talent development and faster regulatory access in the UAE
- Announced
- 8 Jun 2026
Our analysis
Why this matters
Novo Nordisk and the Emirates Drug Establishment (EDE), the UAE's federal medicines regulator, have signed a memorandum of understanding to strengthen cooperation in pharmaceutical manufacturing using advanced technologies, increase in-country value in the supply chain, develop Emirati talent and speed up access to new therapies.
The context is competition among GLP-1 makers in the Gulf. Eli Lilly's contract-manufacturing agreement with Mubadala Bio for Abu Dhabi, logged in this tracker in October 2026, gave a rival a UAE production base. Novo's MoU positions it with the federal regulator that oversees registration and pricing, and opens the door to its own local manufacturing or packaging.
The full analysis is free to read with a work email on this page.
Source: TradeArabia (via IndexBox)